Marine natural product des-O-methyllasiodiplodin effectively lowers the blood glucose level in db/db mice via ameliorating inflammation

Acta Pharmacologica Sinica

Volumn 34, Issue 10, 2013, Pages 1325-1336

  Zhou, Rong ^a   Lin, Zhong Hui ^b   Jiang, Cheng Shi ^b   Gong, Jing Xu ^b   Chen, Li Li ^b   Guo, Yue Wei ^b   Shen, Xu ^a,b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Aldosterone; Blood glucose; Db db mice; Des O methyllasiodiplodin; Diabetes; Glycosylated hemoglobin (HbA1c); Mineralocorticoid receptor; Pro inflammatory cytokine; ROS

Indexed keywords

ALDOSTERONE; DES O METHYLLASIODIPLODIN; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 6; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NATURAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STRAIN 3T3; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURFACE PLASMON RESONANCE; TRANSCRIPTION INITIATION;

3T3-L1 CELLS; ALDOSTERONE; ANIMALS; APOCYNACEAE; BLOOD GLUCOSE; CYTOKINES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, REPORTER; HEMOGLOBIN A, GLYCOSYLATED; HEP G2 CELLS; HUMANS; HYDROGEN PEROXIDE; INFLAMMATION; MACROLIDES; MALE; MICE; OBESITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE;

EID: 84887381740     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.47     Document Type: Article

References (47)

1. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-54. (Pubitemid 40396812)
2. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-9. (Pubitemid 40629025)
3. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273-82. (Pubitemid 38535056)
4. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-6. (Pubitemid 46024990)
5. Harvey AL. Natural products in drug discovery. Drug Discov Today 2008; 13: 894-901.
6. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004; 10: 1344-51. (Pubitemid 40022716)
7. Cheenpracha S, Karalai C, Rat APY, Ponglimanont C, Chantrapromma K. New cytotoxic cardenolide glycoside from the seeds of Cerbera manghas. Chem Pharm Bull (Tokyo) 2004; 52: 1023-5. (Pubitemid 41701891)
8. Chang LC, Gills JJ, Bhat KP, Luyengi L, Farnsworth NR, Pezzuto JM, et al. Activity-guided isolation of constituents of Cerbera manghas with antiproliferative and antiestrogenic activities. Bioorg Med Chem Lett 2000; 10: 2431-4.
9. Norton TR, Bristol ML, Read GW, Bushnell OA, Kashiwagi M, Okinaga CM, et al. Pharmacological evaluation of medicinal plants from Western Samoa. J Pharm Sci 1973; 62: 1077-82.
10. Hien TT, Navarro-Delmasure C, Vy T. Toxicity and effects on the central nervous system of a Cerbera odollam leaf extract. J Ethnopharmacol 1991; 34: 201-6.
11. Jiang CS, Zhou R, Gong JX, Chen LL, Kurtan T, Shen X, et al. Synthesis, modification, and evaluation of (R)-de-O-methyllasiodiplodin and analogs as nonsteroidal antagonists of mineralocorticoid receptor. Bioorg Med Chem Lett 2011; 21: 1171-5.
12. Funder JW, Krozowski Z, Myles K, Sato A, Sheppard KE, Young M. Mineralocorticoid receptors, salt, and hypertension. Recent Prog Horm Res 1997; 52: 247-60; discussion 61-2. (Pubitemid 127470213)
13. Kolla V, Robertson NM, Litwack G. Identification of a mineralo-corticoid/glucocorticoid response element in the human Na/K ATPase alpha1 gene promoter. Biochem Biophys Res Commun 1999; 266: 5-14. (Pubitemid 30028758)
14. + channel. Cell 1995; 83: 969-78. (Pubitemid 26006538)
15. Ferrari P, Ferrandi M, Tripodi G, Torielli L, Padoani G, Minotti E, et al. PST 2238: A new antihypertensive compound that modulates Na, K-ATPase in genetic hypertension. J Pharmacol Exp Ther 1999; 288: 1074-83. (Pubitemid 29254144)
16. Conn JW. Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 1965; 273: 1135-43.
17. Shimamoto K, Shiiki M, Ise T, Miyazaki Y, Higashiura K, Fukuoka M, et al. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hum Hypertens 1994; 8: 755-9. (Pubitemid 24319387)
18. Hitomi H, Kiyomoto H, Nishiyama A, Hara T, Moriwaki K, Kaifu K, et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007; 50: 750-5. (Pubitemid 47442741)
19. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-9. (Pubitemid 43236909)
20. Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, et al. A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens 2007; 25: 2125-30. (Pubitemid 47476311)
21. Haluzik M, Sindelka G, Widimsky J Jr, Prazny M, Zelinka T, Skrha J. Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. J Hum Hypertens 2002; 16: 41-5. (Pubitemid 34134092)
22. Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007; 25: 177-86. (Pubitemid 44885680)
23. Zennaro MC, Caprio M, Feve B. Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol Metab 2009; 20: 444-51.
24. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006; 147: 5363-73. (Pubitemid 44790591)
25. Joffe HV, Kwong RY, Gerhard-Herman MD, Rice C, Feldman K, Adler GK. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007; 92: 2552-8. (Pubitemid 47037357)
26. Matsumoto S, Takebayashi K, Aso Y. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 2006; 55: 1645-52. (Pubitemid 44827131)
27. Takebayashi K, Matsumoto S, Aso Y, Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006; 91: 2214-7. (Pubitemid 43855008)
28. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spirono-lactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-23. (Pubitemid 44871374)
29. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005; 45: 773-9. (Pubitemid 40418380)
30. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21. (Pubitemid 36384098)
31. Wada T, Kenmochi H, Miyashita Y, Sasaki M, Ojima M, Sasahara M, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010; 151: 2040-9.
32. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117: 2253-61.
33. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009; 84: 164-72.
34. Lin Z, Shen H, Huang J, Chen S, Chen L, Chen J, et al. Butyl 4-(butyryloxy)benzoate functions as a new selective estrogen receptor beta agonist and induces GLUT4 expression in CHO-K1 cells. J Steroid Biochem Mol Biol 2008; 110: 150-6.
35. Liu Q, Zhang Y, Lin Z, Shen H, Chen L, Hu L, et al. Danshen extract 15,16-dihydrotanshinone I functions as a potential modulator against metabolic syndrome through multi-target pathways. J Steroid Biochem Mol Biol 2010; 120: 155-63.
36. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-30. (Pubitemid 38063705)
37. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7. (Pubitemid 38032801)
38. Li SL, Valente AJ, Zhao SJ, Clark RA. PU.1 is essential for p47(phox) promoter activity in myeloid cells. J Biol Chem 1997; 272: 17802-9. (Pubitemid 27311221)
39. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, et al. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 2006; 47: 671-9. (Pubitemid 43740237)
40. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005; 16: 2906-12. (Pubitemid 44743488)
41. Garthwaite SM, McMahon EG. The evolution of aldosterone anta-gonists. Mol Cell Endocrinol 2004; 217: 27-31.
42. Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010; 285: 29932-40.
43. Callera GE, Yogi A, Briones AM, Montezano AC, He Y, Tostes RC, et al. Vascular proinflammatory responses by aldosterone are mediated via c-Src trafficking to cholesterol-rich microdomains: role of PDGFR. Cardiovasc Res 2011; 91: 720-31.
44. Fu M, Sun T, Bookout AL, Downes M, Yu RT, Evans RM, et al. A nuclear receptor atlas: 3T3-L1 adipogenesis. Mol Endocrinol 2005; 19: 2437-50. (Pubitemid 41362659)
45. Liu G, Grifman M, Keily B, Chatterton JE, Staal FW, Li QX. Mineralocorticoid receptor is involved in the regulation of genes responsible for hepatic glucose production. Biochem Biophys Res Commun 2006; 342: 1291-6.
46. Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, Han J, et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 2007; 56: 1671-9. (Pubitemid 46842602)
47. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806. (Pubitemid 34000783)